OPKO terminates Phase III trial of macular degeneration candidate

OPKO Health has terminated a Phase III clinical study of its only clinical product, bevasiranib, a siRNA for the treatment of wet age-related macular degeneration (wet-AMD); following a recommendation from the independent data monitoring committee which determined that the trial was unlikely to meet its primary endpoint.